Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...
Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
About one-third of US adults without diabetes who are eligible for weight loss treatment with GLP-1 receptor agonists and GLP-1/GIP receptor agonists meet exclusion criteria for clinical trials.
Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...
Flow Space on MSN13h
Here's What You Need to Know About GLP-1 Drugs Like Ozempic and WegovyGLP-1 receptor agonists, like Ozempic and Wegovy, have been everywhere over the past few years, and research seems to be ...
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...
The connection between weight loss medications and addiction reduction represents a potentially transformative discovery in ...
Antag Therapeutics has announced the closing of an €80 million Series A financing round to develop AT-7687, a novel therapy targeting obesity. The round was led by Versant Ventures, with Novo Holdings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback